Control of bleeding caused by the use of angiography in powder celox

Phase 2

• Conditions: Injury, poisoning and certain other consequences of external causes.; Injuries to the hip and thigh; S70-79

• Registration Number: IRCT201202209084N1
• Lead Sponsor: Vice chancellor for Education, Research and Technology of Qom University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Personal satisfaction of patients, patients candidates for coronary angiography for diagnosis or treatment (angioplasty)
Exclusion criteria: Lack of personal satisfaction of patients for using celox powder, severe skin allergy

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hemostasis. Timepoint: Till stopping bleeding. Method of measurement: With Cronometer.

Secondary Outcome Measures

Name	Time	Method
The severity of andiography location's pain. Timepoint: 6 hours after stopping bleeding. Method of measurement: With 5 degree Likert scale.;Hematoma. Timepoint: 1 hour and 6 hours after stopping bleeding. Method of measurement: Observation of Edema and palpation of angiography location.